Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because the usual routine of meetings, deadlines, and frantic scurrying about has predictably returned. This is especially true for those of you who took an extended break, yes? To cope, we are engaged in yet another routine — brewing cups of stimulation. Our choice today is hot-buttered rum. Rhymes with yum. Meanwhile, here are some tidbits to get you started. Best of luck today and please do keep in touch.

Last August, President Trump proudly proclaimed he had directed the Department of Veterans Affairs to buy “a lot” of esketamine, the first new major depression treatment with a novel mechanism to hit the U.S. market in decades. “Its results are incredible,” Trump said at a veterans convention in Kentucky. As of mid-December, the VA treated just 15 veterans across the country with the drug. The nasal spray, which was developed by Johnson & Johnson (JNJ) and named Spravato, was only available at seven of more than 1,200 agency facilities, STAT tells us.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy